<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94173">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019355</url>
  </required_header>
  <id_info>
    <org_study_id>201303070</org_study_id>
    <nct_id>NCT02019355</nct_id>
  </id_info>
  <brief_title>Actinic Keratosis Study</brief_title>
  <acronym>AK</acronym>
  <official_title>The Role of Calcipotriol in Treatment of Pre-cancerous Skin Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the effectiveness of a new combination
      therapy for actinic keratosis. This study investigates a new indication for an FDA-approved
      topical medication, calcipotriol, for treatment of actinic keratosis, including how well it
      works and how safe it is when used in combination with the standard of care medication
      (5-fluorouracil) for the skin condition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>percentage of change in the number of actinic keratoses from baseline</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the efficacy of topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone in treatment of actinic keratosis in patients with multiple actinic keratoses at each of the four anatomical sites (scalp, face, right upper extremity and left upper extremity). The outcome of interest is percentage change from baseline number of actinic keratoses in the target treatment area on scalp, face, right upper extremity and left upper extremity at 8 weeks after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete and partial (&gt;75%) clearance of actinic keratoses</measure>
    <time_frame>8wks</time_frame>
    <safety_issue>No</safety_issue>
    <description>o	To determine complete and partial (&gt;75%) clearance of actinic keratoses at 8 weeks after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite score of erythema, itching and skin pain after topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone treatment of actinic keratoses</measure>
    <time_frame>4days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the composite scores  of erythema, itching and pain (determined using standardized scales) following topical application of 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone at the end of the 4-day treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of TSLP expression in keratinocytes by calcipotriol</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To examine the induction of TSLP expression in keratinocytes by calcipotriol at the site of the actinic keratoses at the end of 4-day treatment of course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differences in response to topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone between the four anatomical sites</measure>
    <time_frame>8wks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine any differences in response to topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone between the four anatomical sites at 8 weeks after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>calcipotriol plus 5-fluorouracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-fluorouracil plus vaseline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil 5% cream</intervention_name>
    <arm_group_label>calcipotriol plus 5-fluorouracil</arm_group_label>
    <arm_group_label>5-fluorouracil plus vaseline</arm_group_label>
    <other_name>Efudex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol 0.005% ointment</intervention_name>
    <arm_group_label>calcipotriol plus 5-fluorouracil</arm_group_label>
    <other_name>Calcipotriene</other_name>
    <other_name>Dovonex</other_name>
    <other_name>MC 903</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaseline</intervention_name>
    <arm_group_label>5-fluorouracil plus vaseline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of at least 50 years

          -  Presence of four to fifteen clinically typical, visible, and discrete actinic
             keratoses in 25 cm2 on any of the four anatomical sites: scalp, face, right upper
             extremity and left upper extremity

          -  Ability and willingness of the patient to participate in the study (Informed consent
             is obtained)

        Exclusion Criteria:

          -  Treatment area is within 5 cm of an incompletely healed wound or a suspected
             basal-cell or squamous-cell carcinoma

          -  Treatment area contained hypertrophic and hyperkeratotic lesions, cutaneous horns, or
             lesions that had not responded to repeated cryotherapy

          -  Recent (within a month) use of medications that could interfere with evaluation of
             the treatment area (e.g., topical medications, artificial tanners, immunosuppressive
             medications, immunomodulating agents, cytotoxic drugs, ultraviolet B phototherapy,
             other therapies for actinic keratoses, or oral retinoids)

          -  Premenopausal Women (to avoid any risk of pregnancy)

          -  History of hypercalcemia or clinical evidence of vitamin D toxicity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Cornelius, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Tabacchi</last_name>
      <phone>314-362-8171</phone>
      <email>mtabacch@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shawn Demehri, MD,PhD</last_name>
      <email>sdemehri@dom.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shawn Demehri, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Lynn Cornelius, MD</investigator_full_name>
    <investigator_title>Chief, Division of Dermatology</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
